Table I.
Patient characteristics (n=64).
| Variables | Sorafenib (n=20) | NFP (n=44) | P-value |
|---|---|---|---|
| Age (years) | 65.4±8.1 | 63.4±10.0 | 0.426 |
| Sex, n (%) | 0.519 | ||
| Male | 17 (85) | 33 (75) | |
| Female | 3 (15) | 11 (25) | |
| HBs antigen, n (%) | 0.238 | ||
| Present | 5 (25) | 6 (14) | |
| Absent | 15 (75) | 38 (86) | |
| HCV antibody, n (%) | 0.054 | ||
| Present | 8 (40) | 29 (66) | |
| Absent | 12 (60) | 15 (34) | |
| Child-Pugh score, n (%) | 0.787 | ||
| 5 | 10 (50) | 19 (43) | |
| 6 | 10 (50) | 25 (57) | |
| AFP (ng/ml), n (%) | 0.787 | ||
| <1,000 | 5 (25) | 22 (50) | |
| ≥1,000 | 15 (75) | 22 (50) | |
| DCP (AU/ml), n (%) | 0.791 | ||
| <1,000 | 12 (60) | 24 (55) | |
| ≥1,000 | 8 (40) | 20 (45) | |
| Previous treatment, n (%) | 0.787 | ||
| Present | 12 (60) | 28 (64) | |
| Absent | 8 (40) | 16 (36) | |
| Maximum tumor size, mm | 74.3±54.2 | 74.2±33.3 | 0.995 |
| Grade of portal vein invasion, n (%) | 0.124 | ||
| Trunk | 5 (25) | 4 (9) | |
| Branch | 15 (75) | 40 (91) | |
| Hepatic vein invasion, n (%) | 0.486 | ||
| Present | 2 (10) | 8 (18) | |
| Absent | 18 (90) | 36 (82) |
NFP, new 5-fluorouracil and cisplatin therapy; HB, hepatitis B; HCV, hepatitis C virus; AFP, α-fetoprotein; DCP, des-γ-carboxy prothrombin Results are presented as n (%) or mean ± standard deviation.